T-cell prolymphocytic leukemia: Epidemiology and survival trends in the era of novel treatments.
Journal
American journal of hematology
ISSN: 1096-8652
Titre abrégé: Am J Hematol
Pays: United States
ID NLM: 7610369
Informations de publication
Date de publication:
19 Jan 2024
19 Jan 2024
Historique:
revised:
12
11
2023
received:
14
08
2023
accepted:
15
12
2023
medline:
19
1
2024
pubmed:
19
1
2024
entrez:
19
1
2024
Statut:
aheadofprint
Résumé
Survival remains poor for T-cell prolymphocytic leukemia, though treatment in recent years, associated with access to novel therapies, and management at academic medical centers is associated with improved outcomes. There remains a critical need to improve the available treatment options for this population, and access to specialized academic medical centers, comprehensive supportive care, clinical trials, and early palliative care remains essential for T-PLL patients.
Types de publication
Letter
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : NHLBI NIH HHS
ID : 1R38HL143605-01
Pays : United States
Organisme : NCI NIH HHS
ID : R50CA275929
Pays : United States
Informations de copyright
© 2024 Wiley Periodicals LLC.
Références
Swerdlow SH, Campo E, Harris NL, et al., eds. World Health Organization Classification of Tumours of Haematopoietic and Lymphoid Tissues. Revised 4th ed. IARC Press; 2017.
Staber PB, Herling M, Bellido M, et al. Consensus criteria for diagnosis, staging, and treatment response assessment of T-cell prolymphocytic leukemia. Blood. 2019;134(14):1132-1143.
Chandran R, Gardiner SK, Fenske TS, Spurgeon ES. Survival trends in T cell prolymphocytic leukemia: a SEER database analysis. Leuk Lymphoma. 2016;57(4):942-944.
Jain P, Aoki E, Keating M, et al. Characteristics, outcomes, prognostic factors and treatment of patients with T-cell prolymphocytic leukemia (T-PLL). Ann Oncol. 2017;28(7):1554-1559.
Braun T, Jan J, Wahnschaffe L, Herling M. Advances and perspectives in the treatment of T-PLL. Curr Hematol Malig Rep. 2020;15:113-124.
Dearden C. How I treat prolymphocytic leukemia. Blood. 2012;120(3):538-551.